Health Officials Warn of Dangerous Drug Contaminants in B.C.

Health authorities in British Columbia are raising alarms over the increasing presence of medetomidine, a potent veterinary sedative, in the province’s unregulated drug supply. This alarming trend poses heightened risks as medetomidine does not respond to the traditional overdose reversal treatment, naloxone. The B.C. Centre for Disease Control has reported that this drug is being mixed with other depressants, including the highly potent opioid fentanyl.

Medetomidine, primarily used in veterinary settings to manage aggression and for pre-surgical sedation, has been detected in numerous illicit drug samples. The substance is approximately 200 times stronger than xylazine, another non-opioid sedative previously found in B.C.’s drug supply. While medetomidine is approved for veterinary use in Canada, it is not regulated for human consumption, leading to significant health concerns.

Rising Overdose Calls Linked to New Drug Contaminants

In recent months, first responders in Vancouver have observed a troubling spike in overdose calls. On November 21, 2023, the city recorded a staggering 54 overdose calls in a single day, prompting officials to investigate the underlying causes. According to Dr. Mark Lysyshyn, deputy chief medical health officer with Vancouver Coastal Health, the contamination of street drugs with medetomidine and xylazine is increasing the risk of severe health complications.

“The combination of these drugs with opioids or benzodiazepines can significantly heighten the risk of overdose,” Dr. Lysyshyn stated. “While naloxone can reverse opioid overdoses, it is ineffective against medetomidine, leaving users vulnerable.” This situation has prompted health authorities to issue warnings about the dangers posed by these non-opioid sedatives increasingly appearing in illicit substances.

Users of these contaminated drugs may experience intense withdrawal symptoms, which can include high blood pressure, rapid heart rates, and agitation. In Philadelphia, where similar trends have been reported, medetomidine has contaminated an estimated 90 percent of illicit opioids, resulting in hospitals treating many individuals for severe withdrawal symptoms.

Understanding the Risks of Medetomidine

The effects of medetomidine can be severe, leading to cardiac and respiratory depression, prolonged sedation, and other complications. Health officials have noted that symptoms can last from 90 minutes to several hours, especially when combined with other depressants. Reports indicate that some users experience dizziness, nausea, and delusions.

Despite a reported decrease in overall overdose deaths in the past year, the recent influx of medetomidine has raised concerns about non-fatal overdose incidents. Dr. Lysyshyn explained that while naloxone may save lives in cases of opioid overdose, individuals may still require emergency medical intervention due to the sedative effects of medetomidine.

As of early 2024, Vancouver firefighters have responded to 486 overdose incidents, averaging 16 per day, indicating a significant challenge for local emergency services. Chief Karen Fry of Vancouver Fire and Rescue noted, “When we start seeing an increase in calls, we know that something’s changed.”

The B.C. Centre on Substance Use has initiated pilot programs using test strips to detect the presence of medetomidine in street drugs, confirming their effectiveness. However, health officials remain cautious about the long-term implications of this contamination.

The ongoing opioid crisis in British Columbia, declared a public health emergency in 2016, has led to a tragic surge in overdose deaths. In 2023, the province reported its highest number of overdose deaths since the crisis began, with 2,589 fatalities attributed to unregulated drugs, primarily due to fentanyl mixed with other substances.

While naloxone has contributed to saving lives, it cannot prevent the lasting effects of drug toxicity. The current situation calls for heightened awareness among healthcare providers and the public regarding the dangers associated with these emerging contaminants. Health authorities are working to ensure that all medical professionals are informed about the risks posed by medetomidine and similar drugs.

As British Columbia grapples with this evolving crisis, officials continue to seek solutions to mitigate the risks associated with the increasingly toxic unregulated drug supply. Further data and analysis are expected in the coming months as health authorities strive to navigate this complex issue.